Evidence map›Paper›PMID 42143022›Full record

ArticleCell reports. Medicine2026

Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer.

Peter Y F Zeng, Jalna Meens, Amir Hossein Karimi, Harrison Pan, Matthew J Cecchini, Laura Jarycki, Sarah B Ryan, Alice E Dawson, Mushfiq H Shaikh, David A Palma and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Peter Y F ZengDepartment of Otolaryngology - Head & Neck Surgery, Western University, London, ON, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada.
Jalna MeensDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Amir Hossein KarimiDepartment of Otolaryngology - Head & Neck Surgery, Western University, London, ON, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada.
Harrison PanDepartment of Otolaryngology - Head & Neck Surgery, Western University, London, ON, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada.
Matthew J CecchiniDepartment of Pathology and Laboratory Medicine, Western University, London, ON, Canada; Department of Oncology, Western University, London, ON, Canada.
Laura JaryckiDepartment of Otolaryngology - Head & Neck Surgery, Western University, London, ON, Canada.
Sarah B RyanDepartment of Otolaryngology - Head & Neck Surgery, Western University, London, ON, Canada.
Alice E DawsonDepartment of Otolaryngology - Head & Neck Surgery, Western University, London, ON, Canada.
Mushfiq H ShaikhDepartment of Otolaryngology - Head & Neck Surgery, Western University, London, ON, Canada.
David A PalmaDepartment of Oncology, Western University, London, ON, Canada.
Eric WinquistDepartment of Oncology, Western University, London, ON, Canada.
Lakshman GunaratnamDepartment of Microbiology & Immunology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada; Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre Research Institute, London Health Sciences Centre, London, ON, Canada.
Joe S MymrykDepartment of Otolaryngology - Head & Neck Surgery, Western University, London, ON, Canada; Department of Oncology, Western University, London, ON, Canada; Department of Microbiology & Immunology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
John W BarrettDepartment of Otolaryngology - Head & Neck Surgery, Western University, London, ON, Canada.
Paul C BoutrosDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA; Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, USA; Institute for Precision Health, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Centre, University of California, Los Angeles, Los Angeles, CA, USA.
Laurie AillesDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada. Electronic address: laurie.ailles@uhn.ca.
Anthony C NicholsDepartment of Otolaryngology - Head & Neck Surgery, Western University, London, ON, Canada; Department of Oncology, Western University, London, ON, Canada. Electronic address: anthony.nichols@lhsc.on.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic thyroid cancer (ATC) is highly lethal. Although patients with the BRAF

Indexed as

Drug Resistance, NeoplasmMitogen-Activated Protein KinasesProtein Kinase InhibitorsThyroid Carcinoma, AnaplasticThyroid NeoplasmsAnimalsCell Line, TumorHumansMAP Kinase Signaling SystemMiceProto-Oncogene Proteins B-rafPyridonesPyrimidinonesXenograft Model Antitumor AssaysMitogen-Activated Protein KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibacquired resistanceanaplastic thyroid cancerBRAFmouse modelsRAF inhibitorthyroid cancertumor evolutiontumor microenvironment

Identifiers

PMID42143022
PMCPMC13293951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.